Shares of Quest Diagnostics Inc. (DGX) gained 2.7% in trading on Thursday after the company said the Food and Drug Administration had granted emergency use authorization to the company's first at-home COVID-19 test kit. Quest has received EUAs for several tests during the coronavirus pandemic, including for its diagnostic and antibody tests. The at-home test allows adults or their children to gather a nasal sample using a swab at a home and then send out the specimen for shipping using FedEx Corp. (FDX) at the discretion of a health care provider. Quest said it has already tracked individuals collecting their own specimens at drive-through testing sites, including at Walmart Inc. (WMT) locations. That's something ( ) that Quest CEO Steve Rusckowski mentioned on an earnings call in April. Quest's stock is up 11.6% year-to-date, while the S&P 500 is down 6.0%.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
May 28, 2020 13:40 ET (17:40 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.